ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / AURA / insiders
IAM (47) CADL (33) FDMT (44) SLDB (26) ⌘ Pro Terminal →

Aura Biosciences Inc. (AURA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.14 -2.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.10

Aura Biosciences Inc. (AURA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $636.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AURA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Aura Biosciences Inc. (NASDAQ: AURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $6.14 (-2.46% 1D, market cap $636.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AURA ranks #823 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AURA compare to IAM and CADL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IAM (Iambic Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $636.6M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, AURA leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AURA?
▼

Per AURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501796), Aura Biosciences Inc. generated $315.8M in revenue (+17.3% YoY), -$106.2M in net income, and -$85.2M in free cash flow against $169.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.10 (-0.63%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (4)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$10 Bull$5 Base$4 Bear
📬 FREE AURA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AURA)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY AURA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$6.27+4.6% Next Q
Q2 (-2Q)
34
Grade E$6.56-4% Next Q
Q3 (-1Q)
32
Grade E$6.30-2.5% Next Q
Current
29
Grade E$6.14-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AURA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AURA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.62) and Max Pain ($6.45) forces dealer call-delta covering toward $10.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

AURA Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (AURA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on AURA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AURA)

  • ✓Walkthrough of AURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.47%⚡ TESTING RESISTANCE
2026-11-03O $6.29H $6.29L $6.14C $6.14VOL 533.0K
RES: $6.40SUP: $5.31SMA50: $6.62SMA200: $6.73
$9.78$8.74$7.70$6.67$5.63RES $6.40SUP $5.31$6.142026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AURA Butterfly Map → + Track AURA →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AURA)

Health Care Rank #823 of 1016 ⚔️ IAM vs AURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AURA vs. IAM, CADL, FDMT, SLDB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aura Biosciences Inc. (AURA) ranks #823 by composite RQD confidence (29/100, grade E) and #406 by equity capitalization ($636.7M). Within this direct 5-issuer industry benchmark cohort, AURA leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AURA at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AURA ACTIVE
Aura Biosciences Inc.
E 29/100 — — -35.0% -2.46% $636.7M Benchmark Subject
IAM
Iambic Therapeutics Inc.
D 47/100 — — — -5.95% $636.6M /iam-vs-aura →
CADL
Candel Therapeutics Inc.
E 33/100 — — -35.0% -3.70% $637.4M /cadl-vs-aura →
FDMT
4D Molecular Therapeutics Inc.
D 44/100 — — -28.3% -6.89% $657.4M /fdmt-vs-aura →
SLDB
Solid Biosciences Inc.
E 26/100 — — -35.0% -2.97% $664.8M /sldb-vs-aura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001501796

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aura Biosciences Inc. (AURA) reported GAAP revenue of $315.8M (+17.3% vs. FY2024 revenue of $269.1M , and +32.7% cumulative change since FY2023) , GAAP net income of -$106.2M, operating cash flow of -$84.7M, and free cash flow of -$85.2M (-5.1% YoY). On the balance sheet, AURA closed FY2025 with $169.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $315.8M -$106.2M -$84.7M -$85.2M $169.4M —
FY2024 (FY) 2024-12-31 $269.1M -$86.9M -$79.8M -$81.1M $182.5M —
FY2023 (FY) 2023-12-31 $238.0M -$76.4M -$63.8M -$63.8M — —

3. AURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aura Biosciences Inc. (NASDAQ: AURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $6.14 (-2.46% 1D, market cap $636.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AURA ranks #823 in composite RQD confidence.

How does AURA compare to IAM and CADL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IAM (Iambic Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $636.6M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, AURA leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AURA?

Per AURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501796), Aura Biosciences Inc. generated $315.8M in revenue (+17.3% YoY), -$106.2M in net income, and -$85.2M in free cash flow against $169.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AURA trading relative to its 50-day, 200-day, and 52-week technical levels?

AURA last traded at $6.14 (-2.46% on volume of 533,027 shares), positioning the stock -7.25% below its 50-day simple moving average ($6.62) and -8.77% below its 200-day simple moving average ($6.73). Across its 52-week range of $4.73 to $9.53, AURA sits at the 29.4% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($5.57 to $6.71).

Direct Sub-Reports: AURA RQD Cockpit AURA 12M Forecast AURA Earnings & Move AURA Dividends & DRIP AURA Insiders & 13F AURA Whale Options AURA Profit Sankey AURA News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AURA — Aura Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AURA carries an RQD Score of 31 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 7 / 20 (ROIC -35%; FCF yield -13.05%), Whale 13F Flow at 6 / 20 (institutional accumulation and options positioning), Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are cash generation and insider conviction. The insider pillar scoring 3 / 20 signals limited insider-side conviction in the source's measure. The balance sheet pillar is the relative strength, with an Altman Z of 2.5 and Debt/Equity of 0.5, though a Piotroski F of 2/9 points to weak financial-health signals. Institutional and macro pillars are middling. The overall grade is a risk-screening output, not a price target; the upside case requires evidence of a cash-flow inflection that this dataset does not contain.

Business

Aura Biosciences Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances). Reported revenue is — across the FY 2023, FY 2024, and FY 2025 periods per the SEC financials. —

Recent Catalysts & News Wire Analysis

Per the recent news wire, the items are:

  • A Yahoo Finance UK seasonal returns chart item (YELLOW, Market Wire).
  • A Seeking Alpha piece titled "Aura Biosciences: A Pivotal Trial Engineered With Room To Spare" (YELLOW, Market Wire), indicating an upcoming pivotal trial.
  • A TradingView estimates item (YELLOW, Market Wire).
  • A Stock Traders Daily risk-zones item (RED, Risk Watch).
  • A scanx.trade item stating the CEO will speak at a Morgan Stanley healthcare conference (YELLOW, Market Wire).
  • A TradingView item listing a Q3'26 revenue estimate of 0 USD (YELLOW, Market Wire).

Per the Butterfly Supply-Chain Graph, supply_chain is NONE, with no butterfly links and no proprietary signals. The sole RED item is a risk-watch flag from a single trader-oriented source.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or bottleneck links are recorded. —

Analyst View & Smart Money Ownership

Per the analyst data, no analyst coverage is provided. —

Per the holders data, no institutional, insider, or Congressional holdings are provided. —

Open Questions

  • What products or clinical programs drive the operating losses reported for FY 2023–FY 2025?
  • What is the cash runway implied by $59.5M of cash against $-85.2M of FY 2025 free cash flow?
  • What does the referenced pivotal trial measure, and what is its timing?
  • What debt obligations exist, given the reported Debt/Equity of 0.5 but N/A debt figures?
  • Why are EPS and P/E unavailable despite reported net losses?

AURA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aura Biosciences Inc. (AURA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AURA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AURA Bull vs. Bear Conversation Board — What's Your Call at $6.14?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AURA 🐻 67% BEARISH CONVICTION
1. Pick Your Side on AURA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.54 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AURA (E • RQD 31/100) a Buy at $6.30?

Welcome to the AURA (Aura Biosciences Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.04 (-20.0%)
Spot @ $6.30

Pump the brakes on AURA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AURA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aura Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.06 (+27.9%)
Spot @ $6.30

AURA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AURA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $6.30 (52-wk range $4.73 - $9.53), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%